MDPI and ACS Style
Shah, M.A.; Udrea, A.A.; Bondarenko, I.; Mansoor, W.; Sánchez, R.G.; Sarosiek, T.; Bozzarelli, S.; Schenker, M.; Gomez-Martin, C.; Morgan, C.;
et al. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers 2022, 14, 1168.
https://doi.org/10.3390/cancers14051168
AMA Style
Shah MA, Udrea AA, Bondarenko I, Mansoor W, Sánchez RG, Sarosiek T, Bozzarelli S, Schenker M, Gomez-Martin C, Morgan C,
et al. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers. 2022; 14(5):1168.
https://doi.org/10.3390/cancers14051168
Chicago/Turabian Style
Shah, Manish A., Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeño Sánchez, Tomasz Sarosiek, Silvia Bozzarelli, Michael Schenker, Carlos Gomez-Martin, Carys Morgan,
and et al. 2022. "Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies" Cancers 14, no. 5: 1168.
https://doi.org/10.3390/cancers14051168